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The increasing use of antithrombotic drugs in an aging population [including anticoagulants
to prevent future ischemic stroke in individuals with atrial fibrillation (AF)] has been associ-
ated with a dramatic increase in the incidence of intracerebral hemorrhage (ICH) in users of
antithrombotic drugs. Several lines of evidence suggest that cerebral small vessel disease
(particularly sporadic cerebral amyloid angiopathy) is a risk factor for this rare but devastat-
ing complication of these commonly used treatments. Cerebral microbleeds (CMBs) have
emerged as a key MRI marker of small vessel disease and a potentially powerful marker
of future ICH risk, but adequately powered, high quality prospective studies of CMBs and
ICH risk on anticoagulation are not available. Further data are urgently needed to determine
how neuroimaging and other biomarkers may contribute to individualized risk prediction to
make anticoagulation as safe and effective as possible. In this review we discuss the avail-
able evidence on cerebral small vessel disease and CMBs in the context of antithrombotic
treatments, especially regarding their role as a predictor of future ICH risk after ischemic
stroke, where risk-benefit judgments can be a major challenge for physicians.We will focus
on patients with AF because these are frequently treated with anticoagulation. We briefly
describe the rationale and design of a new prospective observational inception cohort study
(Clinical Relevance of Microbleeds in Stroke; CROMIS-2) which investigates the value of
MRI markers of small vessel disease (including CMBs) and genetic factors in assessing
the risk of oral anticoagulation-associated ICH.
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INTRODUCTION AND SCOPE
Over the last decade, increasing use of oral anticoagulants to pre-
vent cardioembolic stroke due to atrial fibrillation (AF) in an
aging population, has been associated with a fivefold increase in
the incidence of anticoagulation-associated intracerebral hemor-
rhage (ICH; Flaherty et al., 2007) – a rare, but unpredictable and
catastrophic complication. Magnetic resonance imaging (MRI)
can identify the presence and severity of cerebral small vessel
diseases, including cerebral amyloid angiopathy (CAA) and hyper-
tensive arteriopathy, which may predispose to ICH in elderly
patients treated with antithrombotic agents (Pantoni, 2010). Key
MRI markers of small vessel disease include cerebral microb-
leeds (CMBs) on T2∗-weighted gradient-recalled echo (T2∗-GRE)
MRI (Greenberg et al., 2009; Charidimou and Werring, 2011) and
leukoaraiosis (also known as white matter changes). Some studies
suggest that leukoaraiosis increases the risk of oral anticoagulant-
associated ICH, but the predictive value is modest (Pantoni, 2010).
CMBs are a more recently recognized imaging finding, which
provides direct evidence of leakage of blood from pathologically
fragile small vessels (Charidimou and Werring, 2011), so they may
logically be a stronger predictor of anticoagulant-associated ICH.
Several lines of evidence support the hypothesis that CMB dis-
tribution in the brain reflects the underlying small vessel disease:
strictly lobar CMBs may relate to CAA, whilst deep CMBs likely
reflect hypertensive arteriopathy (Greenberg et al., 2009; Pantoni,
2010; Charidimou and Werring,2011). The risk of recurrent bleed-
ing after symptomatic ICH seems to be higher for lobar ICH (often
presumed due to CAA; Vinters, 1987; Passero et al., 1995). Lobar
CMBs, suggesting CAA may thus be a stronger risk factor for
antithrombotic-associated ICH than deep CMBs, but definitive
data are lacking. A small prospective study showed that aspirin
might be associated with recurrent lobar ICH in patients with
CAA (Biffi et al., 2010a).
In this review (Table 1) we discuss the available evidence on
CMBs in the context of antithrombotic treatments, especially
regarding their role as a predictor of future ICH risk after ischemic
stroke. We focus on patients anticoagulated after ischemic stroke
associated with AF, and describe the methods and rationale of a
new prospective observational inception cohort study (CROMIS-
21) investigating the value of MRI markers of small vessel disease
(including CMBs) and genetic factors, in assessing the risk of oral
anticoagulation-associated ICH.
ATRIAL FIBRILLATION, ORAL ANTICOAGULATION, AND
ANTICOAGULATION-ASSOCIATED ICH
Atrial fibrillation is the most common sustained cardiac rhythm
disorder and it is increasing in prevalence and incidence because
1http://www.ucl.ac.uk/cromis-2/
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of an aging population (Miyasaka et al., 2006; Lip et al., 2012). The
lifetime risk for developing AF is about one in four for men and
women over the age of 40 (Lloyd-Jones et al., 2004). Untreated, AF
increases the risk of ischemic stroke fivefold – making stroke the
leading complication of AF (Lip et al., 2012). However, this risk
of ischemic stroke increases with the presence of other stroke risk
factors (Hughes and Lip, 2008).
Prevention of ischemic stroke is thus a major therapeutic goal
in AF (Camm et al., 2010), for which oral anticoagulation is very
effective in reducing risk by about 65%. This benefit has to be
balanced against an increased risk of ICH, the most feared com-
plication of oral anticoagulation which causes death or severe
disability in up to 75% of patients (Fang et al., 2007). The careful
assessment of ischemic stroke risk versus anticoagulation-related
ICH risk by physicians is difficult, since paradoxically many of
the known factors that increase ischemic stroke risk overlap with
bleeding risk factors in patients with AF (Lip et al., 2011). This is
illustrated in the current schemes for the assessment of ischemic
stroke (CHA2DS2-VASc) and bleeding risk (HAS-BLED) advo-
cated in the new European guidelines for the management of AF
(Table 2; Camm et al., 2010): prior stroke or TIA and older age
(≥75 years), are strong risk factors for both ischemic stroke and
anticoagulation-associated ICH in patients with AF.
A hospital-based study from the Greater Cincinnati area
showed that the percentage of ICH associated with anticoagu-
lant use increased from 5% in 1988 to 17% in 1999 (Figure 1;
Flaherty et al., 2007). More recent studies from other areas have
revealed similar trends (Kucher et al., 2004; Lovelock et al., 2007).
Population-based data from Oxfordshire, UK (between 1981 and
2006) showed that the incidence of ICH associated with anticoagu-
lant use has substantially increased (rate ratio: 7.4, 95% CI: 1.7–32;
p= 0·007) among patients aged 75 years or older, and that while
the incidence of deep (probably hypertensive arteriopathy-related)
ICH has fallen, the proportion of non-hypertensive lobar bleeds in
those aged 75 years or over increased (odds ratio 4.0, 95% CI: 1.1–
17.4; p= 0.03; Lovelock et al., 2007). It is likely that CAA is impli-
cated in the majority of these lobar hemorrhages and might also
account for the increased incidence of anticoagulation-associated
ICH (see below; Charidimou et al., 2012).
ABSOLUTE RISK OF ICH IN PATIENTS TAKING ANTICOAGULANTS FOR
ATRIAL FIBRILLATION: RCTs VERSUS “REAL LIFE” PRACTICE
The absolute risk of ICH in an individual patient with AF taking
anticoagulants is very difficult to determine from the results of
published clinical studies: the reported rates of ICH vary widely
ranging from 0.1% to more than 2.5% per year (Figure 2; Lip et al.,
2011). These different rates are largely due to the heterogeneity
of patient characteristics included in the studies (including the
proportions with prior stroke and anticoagulant use).
Evidence-based management strategies based on whether a
treatment works (and has its desired effect) are ideally based on
randomized controlled trials (RCTs). However, RCTs designed
to evaluate the efficacy of warfarin in AF may not be the opti-
mum design to investigate rare adverse events (Vandenbroucke,
2011). Randomized trial participants are likely to be selected by
physicians as “good candidates” based on a lower perceived bleed-
ing risk profile and higher likelihood of adherence, or cases in
Table 1 | Search strategy and selection criteria.
References for this review were identified through PubMed (between
January 1990, to April 2012) using the search terms: (a) “microbleed(s),” or
“micro(-)h(a)emorrhage(s),” or “petechial h(a)emorrhage(s),” or
“gradient-echo,” “T2*,” or “susceptibility,” and (b) “atrial fibrillation,”
“anticoagulants,” “warfarin,” and “dabigatran.” The reference list from
retrieved articles, related review articles, clinical guidelines and the
authors’ own files were also searched for relevant publications. Searches
focused on English-language sources and studies in human subjects. The
final reference list was chosen on the basis of relevance to the topics
covered in this article.
Table 2 | Current risk stratification schemes advocated in the new
European guidelines for the management of atrial fibrillation (Camm
et al., 2010) for the assessment of ischemic stroke (CHA2DS2-VASc)
and bleeding risk (HAS-BLED) in patients with atrial fibrillation.
Score
CHA2DS2-VASc
Congestive heart failure 1
Hypertension 1
Age ≥75 years 2
Diabetes mellitus 1
Stroke, TIA, or thromboembolism 2
Vascular diseasea 1
Age 65–74 years 1
Sex category (i.e., female sex) 1
Maximum score 9
HAS-BLEDb
Hypertension (systolic blood pressure>160 mm Hg) 1
Abnormal renal and liver function (1 point each) 1 or 2
Stroke 1
Bleeding tendency or predisposition 1
Labile international normalized ratios (if on warfarin) 1
Elderly (e.g., age >65 years) 1
Drugs or alcohol (1 point each) 1 or 2
Maximum score 9
aPrevious myocardial infarction, peripheral artery disease, or aortic plaque.
b“Hypertension” is defined as systolic blood pressure 160 mmHg. “Abnormal kid-
ney function” is defined as the presence of chronic dialysis or renal transplantation
or serum creatinine≥200 mmol/L. “Abnormal liver function” is defined as chronic
hepatic disease (e.g., cirrhosis) or biochemical evidence of significant hepatic
derangement (e.g., bilirubin.2× upper limit of normal, in association with aspar-
tate aminotransferase/alanine aminotransferase/alkaline phosphatase.3× upper
limit normal, etc.). “Bleeding” refers to previous bleeding history and/or predis-
position to bleeding, e.g., bleeding diathesis, anemia, etc. “Labile INRs” refers to
unstable/high INRs or poor time in therapeutic range (e.g., 60%). Drugs/alcohol
use refers to concomitant use of drugs, such as antiplatelet agents, non-steroidal
anti-inflammatory drugs, or alcohol abuse, etc. INR 1/4 international normalized
ratio. Adapted from Pisters et al. (2010).
TIA, transient ischemic attack.
whom physicians were uncertain as to best treatment, which will
reduce the likelihood of serious adverse events. Indeed, many of
the factors that that are known to increase the risk of bleeding
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are exclusion criteria in many RCTs of anticoagulation in AF.
In six key trials that demonstrated the superiority of warfarin
over placebo in the prevention of thromboembolic complications
in AF, 28,787 patients were screened, but only 12.6% of these
were included in the studies (Levi and Hovingh, 2008). The pro-
portion of patients who are new to warfarin (“warfarin-naïve”
patients) can also modify the results of RCTs, since the risk of both
anticoagulation-associated ICH and ischemic stroke are highest in
FIGURE 1 |The increasing incidence of anticoagulation-associated
intracerebral hemorrhage (ICH), especially in the elderly. Data extracted
from (Flaherty et al., 2007).
newly diagnosed patients with AF and during the first initiation
of anticoagulant medication (Garcia et al., 2010).
Thus, the results of RCTs may not generalize to the “real world”
patient population, and could underestimate the risk of impor-
tant adverse events including ICH. Indeed, there is evidence and
theory suggesting that observational studies are most likely to give
correct estimates of the risk of serious adverse events, which are
unintended and often unpredictable. Observational cohort studies
are likely to have much higher rates of serious adverse effects than
the highly selected populations included in RCTs, which makes this
design a powerful way to assess predictors of risk (Vandenbroucke,
2011).
The reported annual rates of warfarin-associated ICH from
major RCTs of AF (Atrial-Fibrillation-Investigators, 1994; SPAF-
Investigators, 1994; Olsson, 2003; Albers et al., 2005; DiMarco et al.,
2005; Connolly et al., 2006, 2009; Diener et al., 2010; Granger
et al., 2011; Patel et al., 2011) are systematically lower compared
to the rates of ICH of non-inception and inception observational
studies (Landefeld and Goldman, 1989; Fihn et al., 1993; van der
Meer et al., 1993; Steffensen et al., 1997; Beyth et al., 1998; Go
et al., 2003; Hylek et al., 2007; Poli et al., 2009; Figure 2). A
recent observational inception cohort study of patients treated
with oral anticoagulation (of whom a quarter had a previous
history of stroke) reported a 2.5% (95% CI 1.1–4.7%) risk of
ICH at 1 year (Hylek et al., 2007). Because oral anticoagulation-
related ICH is so often fatal or disabling, even a small increase
in the absolute risk of ICH of only 1% per year could potentially
outweigh the benefit of oral anticoagulant treatment (Gustafs-
son et al., 1992), and tip the balance in favor of an alternative
treatment.
FIGURE 2 | Extracted data on reported annual rates of
warfarin-associated ICH from major randomized controlled
trials (RCTs; Atrial-Fibrillation-Investigators, 1994;
SPAF-Investigators, 1994; Olsson, 2003; Albers et al., 2005;
DiMarco et al., 2005; Connolly et al., 2006, 2009; Diener et al.,
2010; Granger et al., 2011; Patel et al., 2011) of atrial fibrillation
compared to non-inception cohort (Fihn et al., 1993; van der
Meer et al., 1993; Go et al., 2003; Poli et al., 2009) and inception
cohort studies (Landefeld and Goldman, 1989; Steffensen et al.,
1997; Beyth et al., 1998; Hylek et al., 2007). *Subgroup analysis of
patients with a previous history of ischemic stroke or transient
ischemic attack in the RE-LY trial.
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NEW ORAL ANTICOAGULANTS
There has been an intense interest in recently developed oral
anticoagulants that are equally efficacious but overcome the well-
known limitations of warfarin, including numerous interactions
with other drugs, the need for regular blood monitoring and dose
adjustments and also have lower risks of intracranial bleeding
(Ahrens et al., 2011; Mega, 2011; Lip, 2012). The new oral antico-
agulants fall into two major categories: (a) the oral direct thrombin
inhibitors (e.g., dabigatran) and (b) the oral factor Xa inhibitors
(the – xabans, including rivaroxaban and apixaban). Of these
agents, dabigatran was recently approved for use for stroke pre-
vention in patients with AF, while rivaroxaban has been approved
by the FDA and the European Union and apixaban is in advanced
phase of clinical development.
Although the reduced risk of ICH reported with the use of
newer anticoagulants is potentially a major advance in safety,
some factors in the study designs merit further consideration
to determine whether this reduced risk will fully translate to the
real world practice of secondary stroke prevention. The landmark
phase III clinical trials for these new agents, the RE-LY (dabi-
gatran; Connolly et al., 2009), AVERROES (apixaban; Connolly
et al., 2011), ARISTOTLE (apixaban; Granger et al., 2011), and
ROCKET-AF (rivaroxaban; Patel et al., 2011) trials, are also sub-
jected to similar criticisms and debates over their designs and
study populations as discussed for warfarin RCTs (Ahrens et al.,
2011). RE-LY (Randomized Evaluation of Long-term Anticoag-
ulation Therapy) study was a non-inferiority trial of dabigatran
versus warfarin (unlike earlier trials that established the superi-
ority of warfarin over placebo); while the ICH rate was around
50–70% lower compared to warfarin, it is worth remembering
that 50% of the participants were already taking warfarin (“war-
farin survivors”) and patients with a recent ischemic stroke or TIA
(within 14 days of randomization) were excluded (Connolly et al.,
2009). These factors might have had an effect on the lower risk of
anticoagulation-associated ICH observed.
In a predefined subgroup analysis of patients who had a history
of stroke or TIA before enrollment in the RE-LY trial (3623/18113,
i.e., 20% of the patients), there was also significant reduction in
ICH with dabigatran (110 and 150 mg twice daily) compared with
warfarin (150 mg RR 0.27, 95% CI: 0.10–0.72; 110 mg RR 0.11,
95% CI: 0.03–0.47; Diener et al., 2010). However, these patients
with a previous history of ischemic stroke or TIA were slightly
younger [mean age (SD): 70.2 (9.4) vs. 71.7 (8.4), p< 0.0001; 70.8
(10.1) vs. 71.7 (8.5),p= 0.008; 70.4 (9.5) vs. 71.9 (8.3),p< 0.0001,
for 110 mg dabigatran, 150 mg dabigatran and warfarin respec-
tively] and more likely to have received warfarin therapy before
enrollment than those without a previous history of stroke or
TIA (51.4% vs. 43·9%, p< 0·0001; 51.3% vs. 44%, p< 0·0001;
52.7% vs. 45.8%, p< 0·0001, for 110 mg dabigatran, 150 mg dabi-
gatran and warfarin respectively; Diener et al., 2010; Lane and Lip,
2010). Similarly, the relative treatment effects (efficacy and safety)
of rivaroxaban (Hankey et al., 2012) and apixaban (Easton et al.,
2012) compared with warfarin were also consistent in subgroup
analyses between patients who had a previous stroke or TIA and
those who had no previous stroke or TIA.
Apart from potential differences in patient characteristics, the
exact mechanisms for the lower rate of ICH with dabigatran
and other new oral anticoagulants compared to warfarin are not
yet known, but might be related to more stable anticoagulation.
Indeed in the RE-LY study, an individual patient level analysis
showed that those with optimal INR control (time of INR within
therapeutic range: 64%) on warfarin had similar rates of hem-
orrhage to dabigatran. Recently, Hart et al. (2012) retrospectively
analyzed the characteristics of 154 intracranial hemorrhages (46%
intracerebral, 45% subdural, and 8% subarachnoid) in 18113 par-
ticipants of the RE-LY trial. They found that the clinical spectrum
of intracranial hemorrhages was similar for patients given war-
farin and dabigatran, but with lower absolute rates of all sites
of intracranial hemorrhage and fatal intracranial hemorrhages
with dabigatran. Here we focus on spontaneous ICH in this sub-
analysis. Independent predictors of spontaneous ICH (n= 63)
overall were: assignment to warfarin (RR: 4.1; p< 0.001), previ-
ous ischemic stroke/TIA (RR: 2.7; p< 0.001), aspirin use (RR: 1.8;
p< 0.02), and age (RR: 1.04 per year; p< 0.02; Hart et al., 2012).
Aspirin use and previous ischemic stroke/TIA predicted ICH in
42 warfarin-assigned patients (i.e., 0.36% per year), but there were
no significant predictors for the 21 events in patients taking dabi-
gatran (i.e., 0.09% per year). Of note, spontaneous ICH occurred
in more warfarin-treated patients with prior ischemic stroke/TIA
than in patients without; however, in patients taking dabigatran,
there was no significant difference (Hart et al., 2012). It could be
argued that patients in the warfarin groups perhaps had a higher
prevalence of bleeding-prone microangiopathies, hence the differ-
ence. Importantly, the mortality associated with spontaneous ICH
averaged 52%, with no significant differences between treatment
arms (Hart et al., 2012). Another interesting point is that patients
with hemorrhagic transformation of their infarcts were excluded
from this evaluation (Hart et al., 2012). Another recent sub-
analysis of the RE-LY trial assessed the risk of bleeding with dabi-
gatran compared with warfarin in older and younger patients with
AF (Eikelboom et al., 2011): they reported that the risk of bleeding
is age dependent, being higher in patients ≥75 years of age (espe-
cially for extracranial bleeding). Oldgren et al. (2011) also reported
that higher CHADS2 scores were associated with increased risks
for stroke or systemic embolism, bleeding, and death in patients
with AF receiving oral anticoagulants in the RE-LY.
With the availability of these new oral anticoagulants (Diener
et al., 2010) it is likely that even more acute cardioembolic stroke
patients will be using oral anticoagulation for secondary stroke
prevention. Although bleeding risks may be lower, therapeutic
reversal options remain limited. At present, there are few outcome
data on these agents outside RCTs (Harper et al., 2012), so natural
history studies and better understanding of the mechanisms and
risk factors of anticoagulation-related ICH will be very important
to allow clinicians to make informed decisions.
MRI PREDICTORS OF ANTICOAGULATION-ASSOCIATED ICH
CEREBRAL SMALL VESSEL DISEASE, CAA, AND CEREBRAL
MICROBLEEDS
Because oral anticoagulant-associated ICH is associated with
increased age and previous stroke, and often occurs with anti-
coagulation intensity within the therapeutic range (Rosand et al.,
2004), it is likely that at least some of the risk is related to individual
patient factors: one hypothesis compatible with available data is
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that the risk of ICH is increased by an age-related disorder of small
brain blood vessels. Anticoagulant use per se should not cause ICH
if cerebral vessels are intact, but the presence of microangiopathy,
rendering small vessels brittle and fragile, is a plausible causal or
aggravating factor for such hemorrhage. Indeed, some risk stratifi-
cation scores (e.g., HAS-BLED; Pisters et al., 2010) includes clinical
elements that may correlate with small vessel disease (e.g., age and
hypertension).
Cerebral small vessel disease is one of the most prevalent brain
conditions described, especially as people live longer (Greenberg,
2006; Pantoni, 2010). The common sporadic forms are: (a) hyper-
tensive arteriopathy (including lipohyalinosis and arterioloscle-
rosis), which typically affects the small perforating end-arteries
of the deep gray nuclei and deep white matter, and as the name
implies is related to hypertension and other traditional cardio-
vascular risk factors (Pantoni, 2010); and (b) CAA, a common
age-related condition characterized by the progressive deposi-
tion of amyloid-β in the media and adventitia of small arteries,
arterioles, and capillaries in the cerebral cortex, overlying lep-
tomeninges, and gray–white matter junction (Charidimou et al.,
2012; Figure 3). The rupture of small arteries affected by these
two disease processes underlies the majority of ICHs (>75%) in
the elderly, classified as spontaneous ICH (sometimes also termed
primary or non-traumatic).
Cerebral amyloid angiopathy is most often recognized in life by
symptomatic, spontaneous, lobar ICH in elderly patients (Charidi-
mou et al., 2012). Evidence supporting a link between CAA and
anticoagulation-associated ICH includes the demonstration of
CAA in 7 of 11 lobar ICHs occurring on warfarin in the largest
consecutive pathological series reported (Rosand et al., 2000). In
addition, the apolipoprotein E e2 allele, a known genetic risk
factor of CAA-related lobar ICH (Nicoll et al., 1997; Biffi et al.,
2010b), is more common in warfarin-associated ICH than in con-
trol patients on warfarin without ICH, supporting a role for CAA
(Rosand et al., 2000). There are also individual cases of ICH fol-
lowing anticoagulation or coronary thrombolysis, which demon-
strated advanced CAA on autopsy (Melo et al., 1993; McCarron
and Nicoll, 2004). However, the mechanisms of spontaneous
and anticoagulation-associated ICH are complex and involve a
dynamic interplay between underlying bleeding-prone small ves-
sel diseases, genetic factors, cardiovascular risk factors, and the use
of oral anticoagulation treatments (Figure 4).
Modern MRI allows an unprecedented ability to identify cere-
bral small vessel disease in vivo. Leukoaraiosis has been recognized
for many years as a characteristic MRI manifestation of small ves-
sel disease. Some studies suggest that the presence of leukoaraiosis
is associated with an increased the risk of oral anticoagulant-
associated ICH (Gorter, 1999; Smith et al., 2002). However,
FIGURE 3 |The distribution of sporadic small vessel disease in the
brain and the topography of cerebral microbleeds (CMBs). (A) Cerebral
amyloid angiopathy (CAA) preferentially affects the small arteries and
arterioles of the cerebral cortex and gray–white matter junction by the
deposition of amyloid-β in the vessel walls (purple); (B) hypertensive
arteriopathy typically affects small deep arterial perforators (black). CMBs
are a marker for the severity and type of small vessel disease; their
anatomic distribution is meant to reflect the underlying pathological vessel
damage. Hence, CMBs (dark, rounded lesions) located in
cortical-subcortical regions are presumably caused by CAA (A), whereas
CMBs located in deep brain regions mainly result from hypertensive
arteriopathy (B). (A) is an axial susceptibility-weighted imaging (SWI)
which is currently the most sensitive means to image CMBs. (B) is an axial
T2*-weighted gradient-recalled echo (T2*-GRE) MRI.
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FIGURE 4 |The pathogenesis of spontaneous and anticoagulation-
associated intracerebral hemorrhage (ICH) involves interaction between
an underlying bleeding-prone small vessel disease (e.g., cerebral
amyloid angiopathy) and the use of oral anticoagulation treatments. This
dynamic interplay is modified at various levels by genetic and ethnic factors
and cardiovascular risk factors. Acute trigger factors for example, sudden
increases in blood pressure or minor trauma may cause the rupture of these
abnormally weak vessels. Anticoagulation may promote ICH by allowing an
otherwise innocuous minor and self-limiting vessel leak to expand into a
life-threatening hematoma.
the pathological substrates of leukoaraiosis are heterogeneous in
nature and severity (ranging from myelin loss, axon loss, and mild
gliosis, to microinfarction and dilation of perivascular spaces)
and hence leukoaraiosis is not a very specific marker of underly-
ing bleeding-prone microangiopathy (Gouw et al., 2010; Schmidt
et al., 2011). The introduction of blood-sensitive MRI sequences,
including T2∗-GRE and susceptibility-weighted imaging (SWI)
has enabled the accurate detection of CMBs (defined radiologi-
cally as small, rounded, homogeneous, hypointense lesions, not
seen with conventional spin echo sequences) as a new imaging
marker of small vessel disease (Greenberg et al., 2009). Histopatho-
logical correlation to date has shown that radiologically defined
CMBs are quite specific for small collections of blood-breakdown
products (in particular, hemosiderin-laded macrophages), adja-
cent to small vessels mainly affected by hypertensive arteriopathy
or CAA (Fazekas et al., 1999; Shoamanesh et al., 2011; Werring,
2011). CMBs are thus unique among current MRI manifestations
of small vessel disease, in that they seem to provide direct evi-
dence of blood leakage from pathologically fragile small vessels
(Charidimou and Werring, 2011).
Several lines of evidence show that CMB distribution in the
brain reflects the underlying small vessel disease: strictly lobar
(cortical-subcortical) CMBs are characteristic of CAA (allowing
the diagnosis of CAA during life using the Boston criteria (Knud-
sen et al., 2001), whilst deep CMBs likely reflect hypertensive
arteriopathy (Figure 3; Greenberg et al., 2009; Pantoni, 2010;
Charidimou and Werring, 2011). If the risk of antithrombotic-
related ICH is related to the underlying arteriopathy type, CMBs
may be of particular value.
HOWMAY CMBs RELATE TO ANTICOAGULATION-ASSOCIATED ICH
RISK?
The plausible mechanism by which CMBs may be linked to
anticoagulation-related ICH depends on the following postulates:
(1) CMBs reflect areas of bleeding from cerebral small vessels.
(2) CMBs are common in the populations likely to be exposed to
anticoagulant drugs (Ueno et al., 2008).
(3) CMBs develop dynamically over time in a significant propor-
tion of patients.
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(4) CMBs that arise are usually “sealed off” by hemostatic fac-
tors or surrounding tissues, thus not causing obvious clinical
symptoms.
(5) In the presence of anticoagulation, some CMBs are not effec-
tively limited by these mechanisms, and may develop into a
serious symptomatic ICH.
Here we briefly consider the evidence for each of these statements.
The available evidence suggests that CMBs are mostly due to
previous small areas of blood leakage from damaged small ves-
sels (Fazekas et al., 1999; Schrag et al., 2009; Shoamanesh et al.,
2011; Werring, 2011) and are common in cerebrovascular disease
and normal aging (Cordonnier et al., 2007). CMBs are increas-
ingly detected in patients with stroke: there are more prevalent
in patients with recurrent stroke than in patients with first-ever
stroke, indicating that they are associated with the progression
of small vessel cerebrovascular disease (Cordonnier et al., 2007)
CMBs are also very common in the general elderly population
and their prevalence increases with age (Sveinbjornsdottir et al.,
2008; Poels et al., 2010). In the Rotterdam scan study, which used
an optimized SWI sequence, the prevalence of CMBs was around
40% in participants over 80 years old (Poels et al., 2010). In this
and other population-based studies lobar CMBs (suggesting sub-
clinical CAA) were detected in up to about 25% healthy elderly
individuals (Sveinbjornsdottir et al., 2008; Mesker et al., 2011),
who are at high risk of AF and ischemic stroke.
Recent studies show that CMBs accumulate over time and are
related to baseline CMBs in population-based healthy elderly and
hospital-based stroke and memory clinic cohorts (Goos et al.,
2010; Gregoire et al., 2010a; Lee et al., 2011; Poels et al., 2011).
Moreover, Jeon et al. (2009) demonstrated the rapid evolving
nature of CMBs even in the acute phase (days) of ischemic stroke.
This study showed the rapid appearance of one or more CMBs
in 12.7% of patients (n= 237) who underwent serial T2∗-GRE
at presentation and after a median of 4 days. The presence of
CMBs at baseline and severe small vessel disease were indepen-
dent predictors of new CMBs. Anticoagulation is hypothesized to
promote ICH by allowing an otherwise innocuous minor and self-
limiting vessel leak (e.g., a CMB) to expand into a life-threatening
hematoma (Hart et al., 1995), especially if the leaking vessel is
damaged by advanced small vessel disease (e.g., CAA). It is hypoth-
esized that CMBs are usually “sealed off” and limited by hemosta-
tic mechanisms and surrounding tissue, but anticoagulants, by
impairing hemostatic mechanisms, increase the likelihood of a
CMB enlarging into a “macrobleed.”
WHAT EVIDENCE IS AVAILABLE ON THE ROLE OF CMBs AS
PREDICTORS OF ICH RISK AFTER ISCHEMIC STROKE?
Available evidence on the relationship of CMBs with spontaneous
and anticoagulation-associated ICH comes from three types of
studies: (a) cross-sectional case-control and case-case compar-
isons; (b) prospective studies; and (c) systematic reviews and
meta-analyses.
Case-control and case-case studies
A numbers of studies have investigated the prevalence of CMBs
in relation to antithrombotic use (Orken et al., 2009; Vernooij
et al., 2009), in antithrombotic users with ICH versus antithrom-
botic users without ICH (Rosand et al., 2000; Ueno et al., 2008),
and antithrombotic-associated ICH versus non-antithrombotic-
associated ICH (Lee et al., 2009). Data from the Rotterdam scan
study showed that CMBs were more prevalent among users of
platelet aggregation inhibitors (adjusted odds ratio: 1.71; 95% CI:
1.21–2.41), compared with non-users of antithrombotic drugs
(Vernooij et al., 2009). In a case–control study comparing 24
patients with warfarin-associated ICH with 48 warfarin users with-
out ICH, the frequency and the number of CMB were much higher
in the ICH group (79.2% vs. 22.9%, p< 0.001; Lee et al., 2009).
Furthermore, increased prothrombin time and the presence of
CMBs were both independent predictors of ICH (Lee et al., 2009).
In another case-control study, lobar CMBs (suggesting possible
CAA) were found to be a risk factor for aspirin-related ICH (Gre-
goire et al., 2010b), in line with the results of a previous report
(Wong et al., 2003). A meta-analysis of published and unpub-
lished data on stroke patient cohorts treated with antithrombotic
drugs attempted to systematically bring together the available evi-
dence (Lovelock et al., 2010). In a pooled analysis of 1460 patients
with ICH and 3817 patients with ischemic stroke or TIA, case-case
comparisons showed that CMBs are more common in warfarin-
related ICH than “spontaneous” ICH (OR: 2.7; 95% CI: 1.6–4.4;
p< 0.001; Lovelock et al., 2010). These results provide indirect
evidence that warfarin could indeed be harmful in patients with
CMBs, but there was no standardization of imaging data or CMB
rating, and data could not be analyzed at an individual patient level
for CMB number or location. Case-control and case-case compar-
isons are useful to tackle rare outcomes, but the choice of control
group is critical to avoid biases and their findings cannot clearly
show causative relationships.
Prospective cohort studies
There are limited prospective studies of CMBs which include
ischemic stroke patients (Fan et al., 2003; Soo et al., 2008; Thijs
et al., 2010), ICH patients (Greenberg et al., 2004; Jeon et al.,
2007) or healthy elderly individuals (Bokura et al., 2011). Table 3
summarizes some key aspects of the main prospective cohort stud-
ies that have assessed the risk of ICH and CMBs in patients after
ischemic stroke or TIA. Many of these studies were not specifically
designed to answer the question of CMBs and antithrombotic ICH
risk, and they also suffer from methodological limitations includ-
ing: (a) small sample size; (b) varied CMB imaging parameters
between studies; and (c) lack of analysis of ICH risk in relation to
CMB number and anatomical location.
In a study of 121 consecutive patients with ischemic stroke,
followed up for 27± 12 months, four patients with CMBs (9.3%)
and one patient without (1.3%) had ICH (p= 0.05; Fan et al.,
2003). Two of the hematomas occurred in the site where CMBs
were found at baseline (Fan et al., 2003). The largest prospective
cohort of CMBs and antithrombotic use included 908 patients
with ischemic stroke, treated with a single antithrombotic agent
(93% with aspirin) with mean follow-up of 26 months (Soo et al.,
2008). Both age and CMBs were found to be independent pre-
dictors of subsequent ICH. During follow-up, it was found that
the risk of ICH increased significantly with the burden of CMBs:
0.6% in patients with no CMB, 1.9% in patients with one CMB,
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Table 3 | Characteristics, study design and methodological aspects of the main prospective cohort studies which have assessed the risk of
future intracerebral hemorrhage in relation to the presence of cerebral microbleeds (CMBs).






















Thijs et al. (2010) Belgium 487 72 32% 1/1.5/3 35/26/16 7 26.5% 2.2 years (median)
Orken et al. (2009) Turkey 141 65.8 – 100% 1.5 15 5 22% 3.94 years (mean)
Soo et al. (2008) China 908 – 92.5% 4.3% 1.5 30 5 27.8% 26.6 months (mean)
Naka et al. (2006) Japan 183 – – – 1 26 5 29% 1.54 years
Boulanger et al. (2006) Canada 236 – 23.7% – 3 20 5 19.1% 14 month (median)
Fan et al. (2003) China 121 68 80% 5.8% 1.5 30 5 35.5% 27.5 months (mean)
4.6% in patients with two to four CMBs and 7.6% in patients
with five or more CMBs (p< 0.001; Soo et al., 2008). In this
study, overall, 15/908 (1.7%) patients suffered ICH at an aver-
age follow-up time of 27 months; of patients with CMBs, 4.4%
developed ICH, whilst 0.6% of patients without CMBs developed
ICH (Soo et al., 2008). Thus the relative risk of the finding of
CMBs for subsequent ICH is 7.3 (4.4/0.6). However, this was an
Asian cohort, and their findings may not be generalizable to other
populations: CMBs were detected in 27.8% of the patients and
were most commonly observed in basal ganglia and thalamus, sug-
gesting that hypertensive arteriopathy was the predominant small
vessel pathology.
It is worth remembering that the presence of CMBs is asso-
ciated with an increased risk of future ischemic stroke as well
as ICH. For example, a recently published prospective follow-up
study (median 2.2 years) of a European cohort of 487 hospitalized
patients with a TIA or ischemic stroke, found that patients with
CMBs had a higher risk of developing new ischemic stroke rather
than ICH (Thijs et al., 2010): during follow-up, only two patients
developed ICH, compared to 32 patients who developed recur-
rent ischemic stroke, and three with undetermined stroke. Only
strictly lobar CMBs (or combined with deep microbleeds) had an
independent effect on the risk of recurrent stroke (p= 0.018; Thijs
et al., 2010).
In pooled follow-up data from 768 antithrombotic users
including the Oxford Vascular Study (OxVASC) cohort (ICH,
ischemic stroke, and TIA patients), CMBs at baseline were asso-
ciated with higher risk of ICH (OR: 12.1, 95% CI: 3.4–42.5,
p< 0.001; Lovelock et al., 2010).
Taken together, prospective studies after ischemic stroke sug-
gest a substantially increased hazard of ICH in the presence of
CMBs (Figure 5), but there is considerable heterogeneity in the
cohorts studied. It is important to note that many of the studies
to date have not used standardized rating scales for CMBs, and
have not reported the ICH risk in relation to CMB anatomical
location. The risk of recurrent bleeding after symptomatic ICH
seems to be higher for lobar ICH (often presumed due to CAA;
Vinters, 1987; Passero et al., 1995). Lobar CMBs may thus be a
stronger risk factor for antithrombotic-associated ICH than deep
CMBs, but data are lacking. A recent single center study of 104
FIGURE 5 | Incidence of intracerebral hemorrhage in relation to the
presence of cerebral microbleeds (CMBs) in the main prospective
cohort studies which have assessed this risk in patients with ischemic
stroke orTIA (Table 3).
survivors of “spontaneous” ICH attributed to CAA demonstrated
that recurrent ICH was associated with baseline lobar CMBs (haz-
ard ratio: 2.93 for 2–4 CMBs and 4.12 for >5 CMBs; Biffi et al.,
2010a).
No large prospective studies of CMBs in ischemic stroke cohorts
treated with anticoagulants for AF have been completed to date,
although this population reflects a common therapeutic dilemma
in clinical practice. Further prospective data will assist the devel-
opment of a reliable risk model, incorporating the most promising
neuroimaging markers of bleeding risk (including CMBs), to aid
anticoagulation decisions in stroke populations who may have the
highest risk of ICH. One large prospective European multicenter
MRI study is currently underway in the UK and is briefly described
in the next section.
CROMIS-2: AIMS AND STUDY DESIGN
The CROMIS-2 (Clinical Relevance Of Microbleeds In Stroke)
study2, aims to establish the value of CMBs (as well as other
2www.ucl.ac.uk/cromis-2
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neuroimaging markers) and genetic factors in predicting sympto-
matic ICH following best practice oral anticoagulation to prevent
recurrent ischemic stroke due to AF.
In summary, CROMIS-2 will set out to answer the following
key questions:
(1) Does the presence of CMBs help predict the risk of sympto-
matic oral anticoagulant-associated ICH in patients who are
anticoagulated following cardioembolic stroke due to AF?
(2) Do the burden (number) and distribution of CMBs at base-
line influence the risk of ICH in this cohort (independently
of other clinical and imaging factors)?
(3) Are CMBs associated with an increased risk of recurrent TIA,
ischemic stroke or death in these patients?
(4) Can we identify new genetic, clinical, or radiological risk
factors of anticoagulant-associated ICH?
These questions will be addressed by two complementary studies
(their inclusion and exclusion criteria are summarized in Table 4).
STUDY I
CROMIS-2 (AF) is a prospective inception cohort study
(n= 1000) of patients throughout the UK started on best practice
oral anticoagulants (without prior use) for presumed cardioem-
bolic ischemic stroke due non-valvular AF. Patients will have
standardized MRI including T2∗-GRE at baseline. Imaging analy-
sis will take place at the co-ordinating center using appropriate
validated rating scales for CMBs and other markers of cerebrovas-
cular disease. Patients with be followed up for an average of 2 years.
The primary outcome will be symptomatic ICH (confirmed on
brain imaging); the secondary outcomes will be recurrent ischemic
stroke or TIA and death of any cause.
STUDY II
CROMIS-2 (ICH) is an observational and genetics study of
ICH: 600 patients admitted to participating centers with sponta-
neous ICH (with a target of at least 300 anticoagulant-associated
ICH cases) will be recruited. Clinical, imaging and genetic data
from these ICH cases will be collected to build a UK-wide
ICH registry for the investigation of risk factors associated
with anticoagulant-related ICH compared to non-anticoagulant-
related ICH. Patients will be followed up at 6 months.
STATISTICAL CONSIDERATIONS
We expect the total ICH rate in our cohort to be at least 2.5%
per year. The relative risk for ICH of having CMBs is not well
established. If we assume a relative risk similar to the one found
in the largest prospective data in an ischemic stroke cohort inves-
tigated for CMBs published to date (i.e., 7.3; Soo et al., 2008),
then we would expect a rate of ICH at 2 years follow-up of 6.5%
in patients with CMBs, compared with 0.9% without CMBs: this
difference would be clinically important and would tip the risk-
benefit judgment in favor of avoiding or reducing the intensity
of oral anticoagulation, or substituting an antiplatelet agent in
patients with CMBs. These estimated risks suggest that we will
observe 30 events in total over a 2-year period (20 in patients with
CMBs, and 10 in those without). The “rule of 10” for developing
risk models suggests that this will allow us to develop a risk model
with three predictor variables in total. A risk model based solely
on CMBs would have a sensitivity of 67% and a specificity of 82%
for predicting an ICH within 2 years. The positive predictive value
would be 14%. A risk model with more variables should improve
on these values.
CONCLUSION
The increasing use of antithrombotic drugs in an aging popula-
tion (including anticoagulants to prevent future ischemic stroke in
individuals with ischemic stroke due to AF) has led to a dramatic
increase in the incidence of ICH associated with antithrombotic
drug use. Several lines of evidence suggest that cerebral small ves-
sel disease (particularly CAA) is a risk factor for this rare but
devastating complication. Although RCTs suggest that the rate of
symptomatic ICH in anticoagulated patients is low (particularly
with the use of new alternatives to warfarin), these studies are not
fully reflective of clinical practice, and are not the optimal way
to investigate predictors of rare adverse events (Vandenbroucke,
2011). CMBs have emerged as a potentially powerful marker of
future ICH risk, but high quality prospective studies of CMBs
and ICH risk on anticoagulation are not available. Further data
are urgently needed to determine how neuroimaging and other
Table 4 | CROMIS-2 inclusion and exclusion criteria.
Inclusion criteria Exclusion criteria
STUDY I: CROMIS-2 (AF)
Adult (≥18y; no upper limit) patients with a clinical diagnosis of non-valvular
AF (verified by ECG) and intention to treat with best practice oral
anticoagulants (e.g., warfarin)
Previous ischemic stroke or TIA diagnosed by treating clinician
All patients must be able to have T2*-GRE MRI before (or within 1 week) of
starting oral anticoagulation
Any MRI contraindications
Previous therapeutic use of oral anticoagulation
Definite contra-indication to oral anticoagulation
Serious head injury (resulting to loss of consciousness)
STUDY II: CROMIS-2 (ICH)
Adult (≥18y) patients treated at participating centers with confirmed
spontaneous ICH (on CT or MRI scans) with or without a history of
anticoagulant use at the time of the ICH
Known underlying structural cause for ICH (e.g., arteriovenous
malformation, tumor, cavernoma, intracranial aneurysm)
Major head trauma (causing loss of consciousness and though to be
sufficient to have caused the ICH) in previous 24 h
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FIGURE 6 | A potential new clinical paradigm of the future role of
neuroimaging markers of small vessel disease and blood/genetic
biomarkers to predict intracerebral hemorrhage (ICH) by guiding
stratified antithrombotic treatment decisions. In this scenario, a
combination of imaging markers could be used to assess the relative
balance of risk for future ischemic stroke or ICH, informing therapeutic
decisions as well as potentially evaluating treatment effects and
monitoring disease progression. Neuroimaging modalities and findings
with potential clinical implications include: (A) cerebral microbleeds on
axial T2*-weighed gradient-recalled echo or susceptibility-weighted
imaging; (B) white matter changes on axial T2-weighted MRI; (C)
amyloid-b load on PET images using radioligands (e.g., Pittsburgh
compound B); and (D) small acute ischemic lesions (possibly cerebral
microinfarcts) on axial diffusion-weighted images.
biomarkers (e.g., genetic variations) may contribute to individu-
alized risk prediction to make anticoagulation as safe and effective
as possible (Figure 6).
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